Brivudine
Phase 3Small molecule
Brivudine is one of 18 small molecule programs targeting Herpes Zoster. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Herpes Zoster
#DrugCompanyPhaseTrials
1Famvir
NovartisApproved
Zovirax
BBp Consulting, Inc
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Foscavir
CClinigen, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Recombinant Zoster Vaccine
MMAXVAX Biotechnology Limited Liability Company
Phase 3
Shingrix
SShenzhen Shenxin Biotechnology Co., Ltd
Phase 2
Recombinant Herpes Zoster Vaccine
BBeijing Luzhu Biotechnology Co., Ltd.
Phase 3
Brivudine
PPeking University Third Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Brivudine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPeking University Third Hospital